All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
2.14 [0.70 ; 6.58 ] Sekine (PLACOVID), 2021 1 0% 160 NA not evaluable death D28detailed results Abuhasira, 2021 0.72 [0.23; 2.24]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Amra, 2021 0.47 [0.12; 1.93]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Davoudi-Monfared, 2020 0.30 [0.11; 0.83]
Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80]
Gharebaghi, 2020 0.00 [0.00; 0.09]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Li, 2020 0.59 [0.22; 1.59]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
O’Donnell, 2021 0.47 [0.21; 1.06]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RECOVER, 2021 1.09 [0.38; 3.13]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
Zhang, 2020 0.50 [0.17; 1.50]
0.80 [0.67 ; 0.95 ] Abuhasira, 2021, AlQahtani, 2020, Aman, 2021, Amra, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Davoudi-Monfared, 2020, Fragoso-Saavedra (PISCO), 2020, Gharebaghi, 2020, HYDRA (Hernandez-Cardenas), 2021, Jamaati, 2021, Kalil (ACTT-3), 2021, Li, 2020, NCT04377750 (HMO-0224-20), 0, O’Donnell, 2021, PICP19 (Ray), 2020, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021, Zhang, 2020 34 28% 5,917 moderate critical death or transfer to ICUdetailed results Lopardo, 2021 0.65 [0.35; 1.22]
0.65 [0.35 ; 1.22 ] Lopardo, 2021 1 0% 241 NA not evaluable deathsdetailed results AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Cao, 2020 0.71 [0.36; 1.40]
CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CAPSID, 2021 0.84 [0.28; 2.50]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COLCHIVID, 2021 0.69 [0.20; 2.40]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
COVID-VIT-D, 2022 1.48 [0.75; 2.92]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
DEVENT, 0 0.47 [0.22; 1.00]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Duke University hydroxychloroquine/azithromycine, 2020 0.50 [0.01; 19.56]
Edalatifard, 2020 0.29 [0.15; 0.56]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Gharebaghi, 2020 0.00 [0.00; 0.09]
Hamed, 2021 1.83 [0.16; 21.66]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96]
INSPIRATION, 2021 1.09 [0.78; 1.53]
Jamaati, 2021 1.19 [0.38; 3.72]
Jamali Moghadam Siahkali, 2021 1.00 [0.19; 5.40]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kumar, 2021 0.06 [0.00; 1.35]
Kumari, 2020 0.60 [0.22; 1.64]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Lopardo, 2021 0.57 [0.24; 1.37]
Ming Zhong, 2020 0.17 [0.02; 1.44]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
Okumuş, 2020 0.58 [0.18; 1.91]
O’Donnell, 2021 0.47 [0.21; 1.06]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Rasheed, 2020 0.13 [0.01; 1.09]
RECOVER, 2021 1.09 [0.38; 3.13]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
Zhang, 2020 0.50 [0.17; 1.50]
0.81 [0.72 ; 0.90 ] AlQahtani, 2020, Aman, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, CAPSID, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COLCHIVID, 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, COVID-VIT-D, 2022, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, DEVENT, 0, DEXA-COVID19, 2020, Duke University hydroxychloroquine/azithromycine, 2020, Edalatifard, 2020, Fragoso-Saavedra (PISCO), 2020, Gharebaghi, 2020, Hamed, 2021, HYDRA (Hernandez-Cardenas), 2021, ILBS-COVID-02 (Bajpai M), 2020, INSPIRATION, 2021, Jamaati, 2021, Jamali Moghadam Siahkali, 2021, Kalil (ACTT-3), 2021, Kumar, 2021, Kumari, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Lopardo, 2021, Ming Zhong, 2020, NCT04377750 (HMO-0224-20), 0, Okumuş, 2020, O’Donnell, 2021, PICP19 (Ray), 2020, PlasmAr, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021, Zhang, 2020 69 32% 15,353 moderate critical deaths (time to event analysis only)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
Edalatifard, 2020 0.29 [0.15; 0.56]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
PlasmAr, 2020 0.93 [0.47; 1.85]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.25 [0.30; 5.14]
Zhang, 2020 0.50 [0.17; 1.50]
0.80 [0.66 ; 0.98 ] COALITION II Covid-19 Brazil (Furtado), 2020, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Davoudi-Monfared, 2020, Edalatifard, 2020, Fragoso-Saavedra (PISCO), 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, PlasmAr, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Talaschian, 2021, Zhang, 2020 16 52% 5,093 moderate low clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
Shu, 2020 0.27 [0.01; 5.58]
Zhang, 2020 0.40 [0.10; 1.65]
0.69 [0.52 ; 0.91 ] CAP-China (Wang et al.), 2020, CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Shu, 2020, Zhang, 2020 6 0% 868 moderate not evaluable clinical improvementdetailed results Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
CAPSID, 2021 1.58 [0.71; 3.49]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Edalatifard, 2020 12.00 [2.39; 60.20]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Lopardo, 2021 1.61 [0.75; 3.49]
Okumuş, 2020 1.51 [0.54; 4.24]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.24 [1.08 ; 1.42 ] Cao, 2020, CAP-China (Wang et al.), 2020, CAPSID, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Edalatifard, 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Lopardo, 2021, Okumuş, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 29 60% 7,416 moderate critical clinical improvement (14-day)detailed results Cao, 2020 1.94 [1.09; 3.48]
CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
Shu, 2020 10.27 [1.17; 90.18]
1.18 [0.93 ; 1.49 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, Li, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Shu, 2020 12 65% 4,045 moderate critical clinical improvement (28-day)detailed results Abuhasira, 2021 1.70 [0.52; 5.49]
Cao, 2020 1.59 [0.84; 3.03]
CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Li, 2020 1.42 [0.65; 3.10]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.24 [0.98 ; 1.57 ] Abuhasira, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 13 38% 2,047 moderate critical clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
Li, 2020 0.98 [0.27; 3.58]
Shu, 2020 6.72 [1.50; 30.07]
1.54 [0.73 ; 3.24 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Li, 2020, Shu, 2020 5 49% 976 moderate not evaluable clinical improvement (time to event analysis only)detailed results Abuhasira, 2021 1.22 [0.70; 2.14]
Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
1.13 [1.02 ; 1.25 ] Abuhasira, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020 14 16% 2,877 moderate critical death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
Veiga, 2021 1.54 [0.65; 3.63]
0.84 [0.60 ; 1.20 ] CAPE-COVID, 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Fragoso-Saavedra (PISCO), 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Veiga, 2021 9 58% 1,732 moderate not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
COLCHIVID, 2021 1.13 [0.76; 1.67]
Davoudi-Monfared, 2020 1.96 [0.76; 5.03]
Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
Rahmani, 2020 3.44 [0.64; 18.49]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
1.00 [0.84 ; 1.19 ] CAPE-COVID, 2020, COLCHIVID, 2021, Davoudi-Monfared, 2020, Fragoso-Saavedra (PISCO), 2020, HYDRA (Hernandez-Cardenas), 2021, Rahmani, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Rosas (REMDACTA), 2021 9 50% 2,524 moderate serious mechanical ventilationdetailed results Abuhasira, 2021 1.62 [0.41; 6.39]
AlQahtani, 2020 0.67 [0.22; 2.02]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Davoudi-Monfared, 2020 0.72 [0.29; 1.76]
Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62]
Hamed, 2021 3.15 [0.57; 17.48]
Jamaati, 2021 1.38 [0.45; 4.20]
Jamali Moghadam Siahkali, 2021 1.30 [0.31; 5.40]
Kumari, 2020 0.76 [0.33; 1.76]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.78 [0.60 ; 1.01 ] Abuhasira, 2021, AlQahtani, 2020, CAPE-COVID, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Fragoso-Saavedra (PISCO), 2020, Hamed, 2021, Jamaati, 2021, Jamali Moghadam Siahkali, 2021, Kumari, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Tabarsi, 2020 21 13% 2,226 moderate low mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
Fragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42]
0.72 [0.35 ; 1.48 ] CP-COVID-19, 2021, Fragoso-Saavedra (PISCO), 2020 2 0% 288 moderate not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
Tabarsi, 2020 2.33 [0.45; 12.00]
3.53 [1.19 ; 10.46 ] Jamaati, 2021, Tabarsi, 2020 2 0% 134 moderate not evaluable viral clearance detailed results CP-COVID-19, 2021 1.12 [0.16; 7.84]
Raman, 2021 36.42 [10.85; 122.18]
6.97 [0.23 ; 210.35 ] CP-COVID-19, 2021, Raman, 2021 2 89% 200 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Raman, 2021 36.42 [10.85; 122.18]
7.68 [0.34 ; 173.70 ] CP-COVID-19, 2021, Raman, 2021 2 90% 200 moderate not evaluable ICU admissiondetailed results Abuhasira, 2021 1.96 [0.51; 7.52]
COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Hamed, 2021 3.15 [0.57; 17.48]
Lopardo, 2021 0.67 [0.35; 1.28]
Rahmani, 2020 0.37 [0.14; 1.00]
Tabarsi, 2020 0.56 [0.18; 1.74]
0.67 [0.47 ; 0.95 ] Abuhasira, 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Hamed, 2021, Lopardo, 2021, Rahmani, 2020, Tabarsi, 2020 9 8% 875 moderate not evaluable Major thrombotic events or deathdetailed results REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36]
1.04 [0.80 ; 1.36 ] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1 0% 1,091 NA not evaluable off oxygenationdetailed results Davoudi-Monfared, 2020 8.57 [1.43; 51.36]
HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88]
sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.35 [0.75 ; 2.46 ] Davoudi-Monfared, 2020, HYDRA (Hernandez-Cardenas), 2021, ILBS-COVID-02 (Bajpai M), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 5 55% 545 serious not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Talaschian, 2021 0.64 [0.14; 2.92]
1.30 [0.64 ; 2.66 ] COV-BARRIER (critically ill), 2022, Talaschian, 2021 2 9% 137 low not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Edalatifard, 2020 0.81 [0.11; 6.17]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.04 [0.87 ; 1.24 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COVACTA (Rosas), 2020, Edalatifard, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Talaschian, 2021, Veiga, 2021 21 27% 7,352 moderate low superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
Davoudi-Monfared, 2020 2.41 [0.75; 7.73]
Rahmani, 2020 0.18 [0.02; 1.59]
0.91 [0.32 ; 2.60 ] CAPE-COVID, 2020, Davoudi-Monfared, 2020, Rahmani, 2020 3 60% 296 moderate not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Raman, 2021 1.36 [0.56; 3.30]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Veiga, 2021 1.65 [0.81; 3.37]
1.12 [0.96 ; 1.31 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Raman, 2021, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Veiga, 2021 11 0% 2,137 moderate low deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
0.50 [0.03 ; 8.10 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
0.36 [0.13 ; 1.01 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
1.09 [0.42 ; 2.79 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable long QTdetailed results COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
0.90 [0.56 ; 1.43 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable Major bleedingdetailed results INSPIRATION, 2021 1.83 [0.53; 6.34]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98]
1.56 [0.85 ; 2.87 ] INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 2 0% 1,653 moderate not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
0.50 [0.03 ; 8.10 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
1.44 [0.98 ; 2.10 ] CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 672 moderate not evaluable Thromboembolic eventsdetailed results INSPIRATION, 2021 1.07 [0.76; 1.49]
1.07 [0.76 ; 1.49 ] INSPIRATION, 2021 1 0% 562 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-08 19:24 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290